Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics to $70 from $85 following quarterly results. The firm keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics price target lowered to $50 from $80 at Evercore ISI
- 3 Stocks to Buy Today, 2/28/2023, According to Top Analysts
- Denali Therapeutics price target lowered to $38 from $46 at Wedbush
- Denali Therapeutics reports Q4 EPS (75c), consensus (79c)
- Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights